Sana Biotechnology (NASDAQ:SANA) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Sana Biotechnology (NASDAQ:SANA) from a sell rating to a hold rating in a report published on Saturday.

A number of other analysts have also recently commented on the stock. HC Wainwright dropped their price target on shares of Sana Biotechnology from $11.00 to $9.00 and set a “buy” rating on the stock in a research note on Friday. JMP Securities set a $8.00 target price on shares of Sana Biotechnology in a report on Thursday, October 30th. Weiss Ratings restated a “sell (e+)” rating on shares of Sana Biotechnology in a research report on Wednesday, October 8th. Citizens Jmp raised their price target on Sana Biotechnology from $5.00 to $8.00 and gave the stock a “market outperform” rating in a report on Thursday, October 30th. Finally, Citigroup reiterated an “outperform” rating on shares of Sana Biotechnology in a research note on Thursday, October 30th. Eight investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Sana Biotechnology has an average rating of “Moderate Buy” and a consensus price target of $8.33.

Sana Biotechnology Stock Performance

SANA stock opened at $4.09 on Friday. The stock has a fifty day moving average of $4.06 and a 200-day moving average of $3.35. Sana Biotechnology has a fifty-two week low of $1.26 and a fifty-two week high of $7.30. The company has a market capitalization of $972.64 million, a price-to-earnings ratio of -4.22 and a beta of 1.94.

Sana Biotechnology (NASDAQ:SANA) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.03. Equities analysts predict that Sana Biotechnology will post -1.16 EPS for the current year.

Institutional Investors Weigh In On Sana Biotechnology

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Wealth Enhancement Advisory Services LLC boosted its stake in Sana Biotechnology by 4.0% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 52,872 shares of the company’s stock valued at $188,000 after buying an additional 2,023 shares during the period. Savant Capital LLC increased its stake in Sana Biotechnology by 5.6% in the 3rd quarter. Savant Capital LLC now owns 66,414 shares of the company’s stock worth $236,000 after acquiring an additional 3,500 shares during the last quarter. Viewpoint Capital Management LLC raised its holdings in shares of Sana Biotechnology by 19.1% in the 2nd quarter. Viewpoint Capital Management LLC now owns 28,045 shares of the company’s stock valued at $77,000 after acquiring an additional 4,500 shares in the last quarter. Captrust Financial Advisors boosted its position in shares of Sana Biotechnology by 43.8% during the 2nd quarter. Captrust Financial Advisors now owns 15,793 shares of the company’s stock valued at $43,000 after acquiring an additional 4,807 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its position in shares of Sana Biotechnology by 46.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 15,444 shares of the company’s stock valued at $42,000 after acquiring an additional 4,931 shares during the last quarter. Hedge funds and other institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.